BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31132650)

  • 1. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.
    Sakhdari A; Ok CY; Patel KP; Kanagal-Shamanna R; Yin CC; Zuo Z; Hu S; Routbort MJ; Luthra R; Medeiros LJ; Khoury JD; Loghavi S
    Ann Diagn Pathol; 2019 Aug; 41():38-42. PubMed ID: 31132650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
    Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
    Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage.
    Dong HJ; Zhou LT; Fang C; Fan L; Zhu DX; Wang YH; Li JY; Xu W
    Med Oncol; 2012 Sep; 29(3):2166-73. PubMed ID: 22057359
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
    Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present.
    Kim DH; Siddiqui S; Jain P; Wang M; Thakral B; Li S; Miranda R; Vega F; Medeiros LJ; Ok CY
    Hum Pathol; 2024 Apr; 146():1-7. PubMed ID: 38460798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.
    Beà S; Valdés-Mas R; Navarro A; Salaverria I; Martín-Garcia D; Jares P; Giné E; Pinyol M; Royo C; Nadeu F; Conde L; Juan M; Clot G; Vizán P; Di Croce L; Puente DA; López-Guerra M; Moros A; Roue G; Aymerich M; Villamor N; Colomo L; Martínez A; Valera A; Martín-Subero JI; Amador V; Hernández L; Rozman M; Enjuanes A; Forcada P; Muntañola A; Hartmann EM; Calasanz MJ; Rosenwald A; Ott G; Hernández-Rivas JM; Klapper W; Siebert R; Wiestner A; Wilson WH; Colomer D; López-Guillermo A; López-Otín C; Puente XS; Campo E
    Proc Natl Acad Sci U S A; 2013 Nov; 110(45):18250-5. PubMed ID: 24145436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smoldering mantle cell lymphoma.
    Ye H; Desai A; Zeng D; Nomie K; Romaguera J; Ahmed M; Wang ML
    J Exp Clin Cancer Res; 2017 Dec; 36(1):185. PubMed ID: 29246179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
    Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J
    Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subclonal evolution of a classical Hodgkin lymphoma from a germinal center B-cell-derived mantle cell lymphoma.
    Schneider S; Crescenzi B; Schneider M; Ascani S; Hartmann S; Hansmann ML; Falini B; Mecucci C; Tiacci E; Küppers R
    Int J Cancer; 2014 Feb; 134(4):832-43. PubMed ID: 23929122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
    Mareckova A; Malcikova J; Tom N; Pal K; Radova L; Salek D; Janikova A; Moulis M; Smardova J; Kren L; Mayer J; Trbusek M
    Leuk Lymphoma; 2019 Jun; 60(6):1420-1428. PubMed ID: 30626249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.
    Klener P; Fronkova E; Berkova A; Jaksa R; Lhotska H; Forsterova K; Soukup J; Kulvait V; Vargova J; Fiser K; Prukova D; Alam M; Calvin Lenyeletse Maswabi B; Michalova K; Zemanova Z; Jancuskova T; Pekova S; Trneny M
    Int J Cancer; 2016 Nov; 139(10):2252-60. PubMed ID: 27407063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
    Jain P; Kanagal-Shamanna R; Zhang S; Ahmed M; Ghorab A; Zhang L; Ok CY; Li S; Hagemeister F; Zeng D; Gong T; Chen W; Badillo M; Nomie K; Fayad L; Medeiros LJ; Neelapu S; Fowler N; Romaguera J; Champlin R; Wang L; Wang ML
    Br J Haematol; 2018 Nov; 183(4):578-587. PubMed ID: 30175400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome.
    Clot G; Jares P; Giné E; Navarro A; Royo C; Pinyol M; Martín-Garcia D; Demajo S; Espinet B; Salar A; Ferrer A; Muntañola A; Aymerich M; Rauert-Wunderlich H; Jaffe ES; Connors JM; Gascoyne RD; Delabie J; López-Guillermo A; Ott G; Wright GW; Staudt LM; Rosenwald A; Scott DW; Rimsza LM; Beà S; Campo E
    Blood; 2018 Jul; 132(4):413-422. PubMed ID: 29769262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management.
    Isaac KM; Portell CA; Williams ME
    Curr Oncol Rep; 2021 Jul; 23(9):102. PubMed ID: 34269910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma.
    Hansen MH; Cédile O; Blum MK; Hansen SV; Ebbesen LH; Bentzen HHN; Thomassen M; Kruse TA; Kavan S; Kjeldsen E; Kristensen TK; Haaber J; Abildgaard N; Nyvold CG
    Exp Hematol; 2020 Apr; 84():7-18.e12. PubMed ID: 32173361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly sensitive and specific
    Federmann B; Frauenfeld L; Pertsch H; Borgmann V; Steinhilber J; Bonzheim I; Fend F; Quintanilla-Martinez L
    Haematologica; 2020 Mar; 105(3):754-764. PubMed ID: 31296581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive leukemic non-nodal mantle cell lymphoma associated with deletions of TP53, ATM, and/or 13q14.
    Chapman-Fredricks J; Sandoval-Sus J; Vega F; Lossos IS
    Ann Diagn Pathol; 2014 Aug; 18(4):214-9. PubMed ID: 24852242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma.
    Jing C; Zheng Y; Feng Y; Cao X; Xu C
    Sci Rep; 2021 Jun; 11(1):11896. PubMed ID: 34099776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in molecular feature of smoldering mantle cell lymphoma.
    Jiang P; Desai A; Ye H
    Exp Hematol Oncol; 2021 Jul; 10(1):41. PubMed ID: 34256839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukemic Non-nodal Mantle Cell Lymphoma: Diagnosis and Treatment.
    Jain AG; Chang CC; Ahmad S; Mori S
    Curr Treat Options Oncol; 2019 Nov; 20(12):85. PubMed ID: 31776787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.